Document Detail


Hypothesized role of pregnancy hormones on HER2+ breast tumor development.
MedLine Citation:
PMID:  23135573     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Breast cancer incidence rates have declined among older but not younger women; the latter are more likely to be diagnosed with breast cancers carrying a poor prognosis. Epidemiological evidence supports an increase in breast cancer incidence following pregnancy with risk elevated as much as 10 years post-partum. We investigated the association between years since last full-term pregnancy at the time of diagnosis (≤10 or >10 years) and breast tumor subtype in a case series of premenopausal Hispanic women (n = 627). Participants were recruited in the United States, Mexico, and Spain. Cases with known estrogen receptor (ER), progesterone receptor (PR), and HER2 status, with one or more full-term pregnancies ≥1 year prior to diagnosis were eligible for this analysis. Cases were classified into three tumor subtypes according to hormone receptor (HR+ = ER+ and/or PR+; HR- = ER- and PR-) expression and HER2 status: HR+/HER2-, HER2+ (regardless of HR), and triple negative breast cancer. Case-only odds ratios (ORs) and 95 % confidence intervals (CIs) were calculated for HER2+ tumors in reference to HR+/HER2- tumors. Participants were pooled in a mixed-effects logistic regression model with years since pregnancy as a fixed effect and study site as a random effect. When compared to HR+/HER2- cases, women with HER2+ tumors were more likely be diagnosed in the post-partum period of ≤10 years (OR = 1.68; 95 % CI, 1.12-2.52). The effect was present across all source populations and independent of the HR status of the HER2+ tumor. Adjusting for age at diagnosis (≤45 or >45 years) did not materially alter our results (OR = 1.78; 95 % CI, 1.08-2.93). These findings support the novel hypothesis that factors associated with the post-partum breast, possibly hormonal, are involved in the development of HER2+ tumors.
Authors:
Giovanna I Cruz; María Elena Martínez; Loki Natarajan; Betsy C Wertheim; Manuela Gago-Dominguez; Melissa Bondy; Adrian Daneri-Navarro; María Mercedes Meza-Montenegro; Luis Enrique Gutierrez-Millan; Abenaa Brewster; Pepper Schedin; Ian K Komenaka; J Esteban Castelao; Angel Carracedo; Carmen M Redondo; Patricia A Thompson
Related Documents :
3725013 - Ct findings in cerebral metastases.
7612003 - Progress on therapy of breast cancer with vitamin q10 and the regression of metastases.
21938273 - Squamous cell carcinoma - similarities and differences among anatomical sites.
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-11-08
Journal Detail:
Title:  Breast cancer research and treatment     Volume:  137     ISSN:  1573-7217     ISO Abbreviation:  Breast Cancer Res. Treat.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-24     Completed Date:  2013-05-27     Revised Date:  2014-06-15    
Medline Journal Info:
Nlm Unique ID:  8111104     Medline TA:  Breast Cancer Res Treat     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  237-46     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Breast Neoplasms / epidemiology,  metabolism*
Female
Gonadal Steroid Hormones / physiology
Hispanic Americans
Humans
Incidence
Logistic Models
Mexico / epidemiology
Middle Aged
Placental Hormones / physiology
Pregnancy
Premenopause
Receptor, erbB-2 / metabolism*
Receptors, Estrogen / metabolism
Receptors, Progesterone / metabolism
Spain / epidemiology
United States / epidemiology
Young Adult
Grant Support
ID/Acronym/Agency:
CA-023074-2953/CA/NCI NIH HHS; P30 CA023074/CA/NCI NIH HHS; P50 CA116199-02S1/CA/NCI NIH HHS; U01 CA153086/CA/NCI NIH HHS; UO1CA153086/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Gonadal Steroid Hormones; 0/Placental Hormones; 0/Receptors, Estrogen; 0/Receptors, Progesterone; EC 2.7.10.1/ERBB2 protein, human; EC 2.7.10.1/Receptor, erbB-2
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast canc...
Next Document:  Tumor scatter after neoadjuvant therapy for rectal cancer: are we dealing with an invisible margin?